Platinum-based therapies are prescribed to 10–15% of cancer patients globally for cancers like lung, breast, bladder, and certain childhood cancers, yet not all patients benefit equally. At CHOSA, we are the only company with a tool that can predict which patients will benefit from cisplatin treatment and which will not.
This precision is critical for personalizing treatment plans and increasing the chances of successful outcomes. We work closely with leading specialists in lung, breast, bladder, head, and neck cancers to bring this life-saving tool to patients worldwide. Our technology further identifies patients who will benefit from the powerful combination of cisplatin and immune therapies, now a gold standard for several cancers, while sparing non-responders unnecessary side effects. By delivering the right treatment to the right patient, CHOSA is setting a new standard for precision medicine and working toward higher response rates.
Company Details
- Employees
- 12
- Address
- Ole Maaløes Vej 3, Copenhagen,capital Region Of Denmark 2200,denmark
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.chosaoncology.com/
- HQ
- Copenhagen, Capital Region of Denmark
Chosa Oncology Questions
Chosa Oncology's website is https://www.chosaoncology.com/
Chosa Oncology's LinkedIn profile is https://dk.linkedin.com/company/chosa-oncology
Chosa Oncology has
12 employees.
View email and phone details for 12
employees at Chosa Oncology.
Chosa Oncology's industry is
Biotechnology Research
Chosa Oncology's top competitors are
Inify Laboratories,
Sundew,
Buhloncology,
Chosa,
Aida Oncology,
Alba Health,
Allarity Therapeutics,
Rhovac,
Cereno Scientific,
Umecrine Cognition Ab.
Chosa Oncology's categories are Biotechnology Research
